Vanguard Fiduciary Trust’s Aptevo Therapeutics APVO Stock Holding History

Vanguard Fiduciary Trust’s Portfolio APVO Stock Details APVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.4K	Hold	4,142	–	–	﹤0.01%	4005
2026 Q1	$17.7K	Buy	+4,142	New	+$28.3K	﹤0.01%	3967

Other funds holding APVO

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Vanguard Fiduciary Trust's APVO Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Aptevo Therapeutics (APVO) position steady in Q2 2026 at 4,142 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4005.

Vanguard Fiduciary Trust first reported a position in APVO in Q1 2026 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold APVO as of Q2 2026.

Vanguard Fiduciary Trust held 4,142 shares of Aptevo Therapeutics worth $18.4K as of Q2 2026.
Vanguard Fiduciary Trust left its Aptevo Therapeutics share count unchanged in Q2 2026.
Aptevo Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #4005 holding.
Vanguard Fiduciary Trust first reported a position in Aptevo Therapeutics in Q1 2026 and has held it in 2 quarters since.
9 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.